Pharmacy-to-Pharmacy DSCSA Transactions: MedmartRx Automates Wholesale Distribution Documentation

MedmartRx, a digital marketplace connecting licensed pharmacies for surplus inventory transactions, now generates DSCSA-compliant transaction documentation automatically. The platform produces Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS) records at the point of sale, eliminating manual documentation for inter-pharmacy wholesale transfers. This automation addresses a persistent compliance friction point: retail pharmacies engaging in occasional wholesale distribution without dedicated compliance infrastructure.

Regulatory Context

Under the Drug Supply Chain Security Act (21 U.S.C. 360eee-1), any entity that distributes prescription drugs in interstate commerce meets the statutory definition of a "wholesale distributor" — even if wholesale distribution is not their primary business. A retail pharmacy selling surplus inventory to another pharmacy across state lines is, for that transaction, acting as a wholesale distributor and must comply with 21 CFR Part 205 and DSCSA's transaction documentation requirements.

DSCSA requires that all prescription drug transactions include:

1. Transaction Information (TI): proprietary or established name, strength, dosage form, NDC, container size, number of containers, lot number, transaction date, shipment date
2. Transaction History (TH): documentation of prior ownership, from manufacturer to current trading partner
3. Transaction Statement (TS): attestation that the product is legitimate, was received from an authorized trading partner, and was not knowingly counterfeited, diverted, or adulterated

For retail pharmacies without wholesale distribution as a core function, assembling these documents manually is time-prohibitive. Many smaller pharmacies avoid selling surplus inventory to out-of-state buyers solely to avoid the compliance burden, even when the transaction would be economically beneficial and legally permissible.

How MedmartRx Addresses the Documentation Gap

MedmartRx's compliance engine cross-references product data, transaction metadata, and trading partner credentials to populate DSCSA documents at checkout. The platform:

• Auto-fills TI fields from NDC database entries and seller-provided lot/expiration data
• Aggregates TH records by requiring sellers to upload prior documentation or attest to manufacturer-direct acquisition
• Generates TS attestations based on state licensure verification and trading partner authorization checks

Both buyer and seller receive PDF and EDI (EPCIS 1.2) versions of the documentation set. The platform stores records for six years, meeting the statutory retention requirement under 21 U.S.C. 360eee-1(b)(4).

MedmartRx verifies both parties hold active pharmacy licenses in their respective states before enabling transactions. The platform does not verify whether sellers hold separate wholesale distributor licenses — a gray area in enforcement. Most state boards of pharmacy do not require a separate wholesale license for incidental surplus sales by retail pharmacies, but interpretations vary. California, for example, has historically required separate licensure even for occasional wholesale activity (Bus. & Prof. Code § 4160).

Operational Implications for Wholesale Distributors

For licensed wholesale drug distributors, MedmartRx represents competition in the spot market for slow-moving and overstocked inventory. Pharmacies that previously relied on wholesalers to take back surplus (often at significant discounts) can now transact directly with other pharmacies at negotiated prices. This disintermediates the traditional wholesaler return channel.

For 3PLs providing warehousing and distribution services to retail pharmacies, the platform's automated documentation may reduce demand for compliance support services that previously helped pharmacies navigate wholesale transactions.

For cold chain logistics providers, MedmartRx does not currently integrate temperature monitoring or cold chain validation into its compliance workflow. Pharmacies selling temperature-sensitive products via the platform must still arrange shipping separately and ensure cold chain integrity through third-party logistics providers. This leaves a service gap for specialty products requiring 2-8°C storage.

The platform's documentation automation does not exempt transactions from state-specific wholesale distribution reporting requirements. Pharmacies using MedmartRx must still file pedigree reports, transaction logs, or suspicious order monitoring reports where required by state law.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 licensed wholesale drug distributors and 3PLs across 51 jurisdictions. Of these, 1,234 hold active FDA registration — a baseline compliance signal required for all entities engaging in wholesale distribution. The average compliance score in the directory is 51/100, placing most entities in the "Fair" tier. This suggests that while basic registration requirements are widely met, secondary compliance signals (NABP accreditation, state licensure breadth, enforcement history) are less consistent.

MedmartRx's automation of DSCSA documentation affects a category of wholesale transactions that ColdChainCheck does not yet comprehensively track: retail pharmacies engaging in incidental wholesale distribution. The directory focuses on entities whose primary business is wholesale distribution or third-party logistics. Retail pharmacies acting as occasional wholesale distributors typically do not appear in state wholesale distributor license databases unless they have formally applied for dual licensure.

This creates a blind spot. When a QA manager runs a trading partner qualification check, they expect to find entities in either:

1. State board of pharmacy wholesale distributor license databases
2. FDA's drug establishment registration database
3. NABP's VAWD/DAC directories

Pharmacies using MedmartRx to sell surplus inventory may only appear in retail pharmacy license databases, not wholesale distributor databases — even though they are functionally acting as wholesale distributors for those transactions. This complicates due diligence.

Practical Guidance for Compliance Officers

• Before accepting surplus inventory from a pharmacy-to-pharmacy platform, verify the seller holds an active retail pharmacy license in their home state. Use ColdChainCheck's state-specific license directories to confirm status. If the seller is listed as a wholesale distributor, check their compliance score to assess broader regulatory posture.

• For multi-state transactions, confirm the seller is authorized to distribute into your state. Some states require non-resident wholesale distributor licenses even for single transactions. ColdChainCheck tracks license jurisdiction coverage for 1,275 entities; cross-reference the seller's home state licenses against your receiving state's requirements.

• Request NABP accreditation verification if the transaction involves controlled substances or high-value specialty drugs. Only 63 entities in ColdChainCheck's directory hold NABP accreditation (formerly VAWD), representing a small subset of verified wholesale distributors. Pharmacy-to-pharmacy platforms generally do not require sellers to hold NABP accreditation, increasing counterfeiting and diversion risk.

• Check for enforcement history before establishing a new trading partner relationship. ColdChainCheck tracks 73 entities with FDA recalls, warning letters, or consent decrees on record. A pharmacy with a history of compounding violations or dispensing infractions may present higher risk as a wholesale trading partner, even if their retail license is active.

MedmartRx's automated DSCSA documentation satisfies federal transaction record requirements but does not replace trading partner authorization due diligence. Use ColdChainCheck's directory to verify licensure and compliance posture before completing transactions initiated on pharmacy-to-pharmacy marketplaces. For a comprehensive overview of DSCSA requirements and trading partner verification workflows, see the DSCSA Compliance Checklist for Wholesale Distributors.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Entities should consult qualified legal counsel and verify all compliance requirements with the relevant state board of pharmacy and FDA before engaging in wholesale drug distribution.